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ABSTRACT
Clinical and preclinical data indicate that tumor necrosis factor (TNF)– is an important mediator of acute
graft-versus-host disease (aGVHD) after allogeneic bone marrow transplantation. We completed a study using
etanercept, a fusion protein capable of neutralizing TNF-, for the initial treatment of aGVHD. Etanercept (25
mg subcutaneously) was administered twice weekly for 16 doses, along with methylprednisolone (2 mg/kg) and
tacrolimus for biopsy-proven aGVHD. Twenty patients with a median age of 47 years (range, 8-63 years) were
enrolled. Fourteen patients with grade II aGVHD (11 family donors and 3 unrelated donors) and 6 patients
with grade III aGVHD (3 family donors and 3 unrelated donors) were treated. Twelve patients completed 16
doses of therapy, and 8 received 5 to 15 doses. Reasons for not completing all doses of etanercept included
progression of aGVHD (n  4), relapsed leukemia (n  2), progression of pulmonary and central nervous
system lesions (n  1), and perforated duodenal ulcer (n  1). Fifteen (75%) of 20 patients had complete
resolution of aGVHD within 4 weeks of therapy. Increasing levels of soluble TNF receptor 1 plasma
concentration during the first 4 weeks of therapy indicated progression of aGVHD in 5 patients. In contrast,
for 15 responding patients, soluble TNF receptor 1 plasma concentration levels returned to baseline. These
data demonstrate the feasibility of using cytokine blockade in the early treatment of aGVHD.
© 2005 American Society for Blood and Marrow Transplantation
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cNTRODUCTION
Acute graft-versus-host disease (aGVHD) remains
he most signiﬁcant and potentially lethal complica-
ion of allogeneic bone marrow transplantation
BMT). Depending on the intensity of the condition-
ng regimen, the extent of histocompatibility differ-
nces with the donor, the age of the recipient, and the
tage of the primary disease, the incidence of aGVHD
ay vary from 20% to 70% [1-6]. Methylpred-
isolone remains the standard initial treatment of
GVHD, but even with prompt initiation of such
herapy, the treatment is suboptimal. The 2 largest
tudies on the primary treatment of aGVHD report o
80omplete response (CR) rates of 20% and 35% [7,8].
ttempts to improve the CR rate by adding antithy-
ocyte globulin [9] or using higher doses of cortico-
teroids [10] have been unsuccessful. Moreover, treat-
ent of steroid-resistant GVHD has a very low
esponse rate, and no treatment is considered standard
11].
Recent studies from murine models implicate ex-
essive production of inﬂammatory cytokines, includ-
ng tumor necrosis factor (TNF)–, as signiﬁcant con-
ributors to the induction and ampliﬁcation of
VHD, and a strong correlation exists between in-
reases in serum TNF- levels and the development
f GVHD [12-16]. The cytotoxic damage of target
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Etanercept and Methylprednisolone for aGVHD
Brgans by GVHD may also be mediated by inﬂam-
atory cytokines [17]. In addition, human trials have
emonstrated associations between TNF- levels and
he development of aGVHD after allogeneic BMT
18-20].
Studies have evaluated various monoclonal anti-
odies that inhibit TNF- for the prevention and
reatment of GVHD [21,22]. Although these trials
howed some initial success, they demonstrated that
nhibition of TNF- may need to be sustained and/or
ombined with other agents to maximize clinical efﬁ-
acy. More recently a new monoclonal antibody with
NF-–binding afﬁnity, inﬂiximab, approved for use
n the treatment of Crohn’s disease and various rheu-
atologic diseases [23,24], was shown to have efﬁcacy
n GVHD control, but it may be associated with a
igh rate of infectious complications, including non-
andidal fungal infections [25-28].
On the basis of these data, we initiated a pilot
tudy on the use of etanercept and methylpred-
isolone as primary treatment for patients with grade
I or III aGVHD. Etanercept (Enbrel; Amgen Corp.,
housand Oaks, CA) is a recombinant human TNF-
eceptor type II fusion protein that has been used
uccessfully for the treatment of several rheumato-
ogic diseases [29,30]. Previous reports on etanercept
n the treatment of GVHD have included a single case
eport [31] and a series of 7 patients treated for
hronic GVHD [32]. In this study, we evaluated the
se of etanercept administered with methylpred-
isolone as the primary treatment of aGVHD. The
rimary end point of the study was toxicity, and sec-
ndary end points included the response of aGVHD
o treatment and the measurement of cytokine proﬁles
efore and after treatment.
ATERIALS AND METHODS
atients
Patients undergoing allogeneic BMT from either
amily donors (FD) or volunteer unrelated donors
UD) for hematologic malignancies were eligible for
his study. All patients received tacrolimus and low-
ose methotrexate (5 mg/m2 on days1,3,6, and
11, with leucovorin rescue on days 3, 6, and
11) for GVHD prophylaxis. Four patients who re-
eived reduced-intensity regimens received mycophe-
olate mofetil 10 mg/kg every 8 hours on days 6 to
8 in addition to tacrolimus and methotrexate for
VHD prophylaxis and to aid in engraftment. After
ngraftment, all patients received prophylactic tri-
ethoprim-sulfamethoxazole DS orally twice daily 2
imes a week for Pneumocystis carinii pneumonia pro-
hylaxis, ﬂuconazole 100 mg once a day for fungal
rophylaxis, and ganciclovir 5 mg/kg twice weekly for
ytomegalovirus prophylaxis if the patient or donor T
B&MTas cytomegalovirus positive. In addition, patients
ho were positive for varicella-zoster virus or had a
istory of infection with varicella-zoster virus were
iven acyclovir 800 mg twice daily for 1 year.
Inclusion criteria included biopsy-proven
GVHD, clinical grades II to III, and achievement of
eutrophil engraftment. GVHD was staged and
raded by using consensus criteria [33]. Liver GVHD
as diagnosed in patients with hyperbilirubinemia,
ther target organ manifestations of GVHD, and the
bsence of other causes of liver dysfunction as docu-
ented by noninvasive techniques.
Exclusion criteria included progression to clinical
rade IV aGVHD before the initiation of etanercept,
ctive infection unresponsive to antibiotic therapy,
enal insufﬁciency (serum creatinine 2.0 mg/dL),
ypotension secondary to sepsis syndrome and/or re-
uiring pressor support, and heart failure requiring
notropic support. No patient could have received
ethylprednisolone (2 mg/kg/d) for longer than 72
ours before treatment with etanercept. The study
as approved by the University of Michigan Institu-
ional Review Board, and all patients signed institu-
ional review board–approved consent before entering
he trial.
reatment
This study was an open-label pilot study. Patients
ith aGVHD were treated with tacrolimus and meth-
lprednisolone 2 mg/kg/d. Etanercept 25 mg (0.4
g/kg for patients 0.6 m2) was administered subcu-
aneously twice a week for 8 weeks (maximum dose of
tanercept was 25 mg). Etanercept was supplied by the
mgen Corporation. No dose of etanercept was ad-
inistered within 72 hours of a prior dose. Study
atients continued on methylprednisolone and ta-
rolimus with appropriate serum levels for GVHD
ontrol. Methylprednisolone was maintained at a dose
f 2 mg/kg/d for at least 1 week after the initial
esponse to therapy and was then tapered as appro-
riate. If patients achieved a CR to therapy for
VHD, the following guidelines were used for taper-
ng methylprednisolone: 50% dose reduction (1 mg/
g) after 1 week of achieving a CR, 25% of the orig-
nal dose (0.5 mg/kg) within 4 weeks, and 12% of the
riginal dose (0.25 mg/kg) by 8 weeks. Dose reduc-
ions of methylprednisolone for steroid-related toxic-
ty during the initial 7 days of etanercept therapy were
llowed.
oxicity Grading and GVHD Assessment
Patients were evaluated twice weekly for the ﬁrst 4
eeks of the study and then weekly for the ﬁnal 4
eeks. The severity of GVHD and all adverse events
ere recorded weekly from the start of treatment.
oxicities were measured by the National Cancer
681
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6nstitute Common Toxicity Criteria. Patients re-
oved early from the study continued to be evaluated
or 30 days for evidence of toxicity. Otherwise, pa-
ients were followed up for the full 8 weeks of the
tudy. A CR was deﬁned as the resolution of all man-
festations of GVHD (all organs stage 0) within 8
eeks of the initiation of etanercept. A partial re-
ponse was deﬁned as a decrease in the severity of
VHD by at least 1 overall grade without deteriora-
ion of any organ system. Progression was deﬁned as
ny new organ involvement, a worsening of 1 grade of
he GVHD requiring additional systemic therapy, or
eterioration of the patients’ condition at any time
uring the 8-week administration of etanercept. Et-
nercept was discontinued in patients who had pro-
ression of aGVHD requiring additional systemic
herapy. Patients who did not meet the criteria of
ither a partial response or progression were catego-
ized as having no response. A ﬂare was deﬁned as
ny patient who achieved a CR but had worsening
f 1 grade of GVHD requiring additional systemic
herapy.
ytokine Analysis
Blood samples were obtained from patients before
he initiation of treatment and then weekly during
reatment. The plasma component of each sample was
nalyzed for the soluble TNF receptor 1 (sTNFR1)
evels by the Immunologic Monitoring Core Labora-
ory of the Cancer Center by using cytokine enzyme-
inked immunosorbent assay (Genzyme, Cambridge,
A). The assays were performed according to the
anufacturer’s protocol, and all samples and stan-
ards were run in duplicate. Before transplantation, all
tudy subjects gave separate consent to the collection
f blood samples at regular intervals before and after
MT. Plasma levels of sTNFR1 were 2240  297
g/mL before transplantation. To normalize the
TNFR1 levels, ratios of sTNFR1 levels were created
y comparing the level at the time of sample collection
onset of GVHD and 2 and 4 weeks after the study
rug was initiated) with the lowest pretransplantation
evel. The means of these ratios were compared by
sing the Student t test. P values .05 were consid-
red statistically signiﬁcant. The changes in sTNFR1
atios over time between responders and nonre-
ponders were compared by repeated-measures anal-
sis of variance.
ESULTS
atient Demographics
Twenty patients were enrolled between Novem-
er 2001 and June 2003. The median age was 47 years
range, 8-63 years). Sixteen patients underwent full-
ntensity regimens, and 4 had reduced-intensity regi- p
82ens. Fourteen patients received peripheral blood
tem cells from 6/6 HLA-identical FDs. Six patients
eceived UD transplants (4 bone marrow and 2 pe-
ipheral blood stem cells). One UD was a 5/6 HLA
atch (antigen mismatch at the B locus).
Fourteen of the 20 patients had grade II aGVHD
11 FD and 3 UD transplants). Six patients had grade
II aGVHD (3 FD and 3 UD). The diagnosis of
VHD was conﬁrmed by the biopsy of at least 1
rgan in each patient. Nine patients had a skin biopsy
s their only biopsy site of GVHD. Eleven patients
ad clinical symptoms of GVHD of the gastrointesti-
al (GI) tract conﬁrmed by biopsy. Two patients un-
erwent lower GI biopsies and 1 upper GI biopsy to
onﬁrm GVHD. Eight patients had both upper and
ower endoscopies; 6 had histologic changes of
VHD in both areas, and 1 patient each had lower or
pper GI involvement.
tanercept Administration
Twelve of 20 patients received all 16 doses of
tanercept. Drug administration was well tolerated,
ith the exception of a single patient who developed
ives and pruritus after the initial dose of etanercept
hat resolved with antihistamines. One patient (no. 8)
ith a history of deep venous thrombosis, who had
iscontinued anticoagulation before BMT, developed
pulmonary embolism after receiving 2 doses of et-
nercept. Anticoagulation therapy was restarted, and
he full course of etanercept was completed. A second
atient (no. 9) was admitted to the hospital with hy-
otension 7 days after receiving the ﬁnal dose of et-
nercept. The patient was diagnosed with gram-
ositive bacteremia, was successfully treated with vig-
rous ﬂuid resuscitation, and was discharged home.
Eight patients received 5 to 15 of the planned 16
oses of etanercept. Four (nos. 11, 14, 18, and 19) of
hese 8 patients discontinued therapy after progres-
ion of their GVHD. Two patients (nos. 13 and 20)
ho had refractory leukemia at the time of transplan-
ation relapsed while on the study, and all immuno-
uppressive therapy was discontinued. One patient
no. 17) with a history of lymphoma developed pul-
onary and central nervous system nodules of pre-
umed fungal etiology while on study. Because of the
ossibility of infection, etanercept was discontinued,
ut no organism was identiﬁed on cultures. The pa-
ient died, and the cause of the lesions was never
dentiﬁed. One patient (no. 3) discontinued etanercept
fter 7 doses because she developed a perforated du-
denal ulcer that required surgical repair. She was in a
omplete remission of her aGVHD 1 week after dis-
ontinuation of etanercept and recovered fully from
er operation. Four additional serious infections were
ocumented during etanercept administration. Two
atients developed bacteremias, and 1 developed cy-
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Etanercept and Methylprednisolone for aGVHD
Bomegalovirus viremia. All resolved with standard
reatment. A fourth patient, with progressive GVHD
no. 19), was noted to have disseminated fungal dis-
ase at autopsy. No patient developed toxicity that was
robably or deﬁnitely attributable to etanercept.
esponses to Etanercept
Fifteen (75%) of 20 patients had a CR (Table 1).
ll 15 patients who achieved a CR did so within 4
eeks of starting therapy (8 doses). During the 72-
our period between the initiation of steroids and the
tart of etanercept, 4 patients (1 CR and 3 partial
esponses) responded to steroids. Only 1 patient in
R developed a ﬂare of GVHD while receiving etan-
rcept; the GVHD responded to the reinstitution of
ethylprednisolone 2 mg/kg. A second patient expe-
ienced a ﬂare of GVHD 1 week after completion of
tanercept that also completely responded to reinsti-
ution of full-dose methylprednisolone. Of the 15 re-
ponders, 11 received all 16 doses of etanercept. The
edian dose of methylprednisolone by week 4 of
reatment in these 11 patients was 0.45 mg/kg (range,
.26-0.66 mg/kg). By week 8 of therapy, the median
ose was 0.18 mg/kg (range, 0.0-2.0 mg/kg). In the 4
esponders who did not complete the full 8 weeks of
herapy, the median dose of methylprednisolone was
.5 mg/kg (range, 0-1.0 mg/kg) at the time etanercept
as discontinued. In the 5 nonresponders, the median
ose of methylprednisolone at the time of progression
as 1.75 mg/kg (range, 0.5-2.0 mg/kg).
The pattern of responses to therapy is shown in
able 2. Twelve of 14 recipients of FD BMT had CRs
10/11 with grade II and 2/3 with grade III aGVHD).
hree of 6 patients who received UD transplants
esponded completely; all had grade II aGVHD.
leven of 12 patients with single-organ involvement
xperienced a CR: 7 of 7 with skin and 4 of 5 with GI
nvolvement. Four of 8 patients with 2-organ involve-
ent achieved a CR: 3 of 4 with skin and GI involve-
ent and 1 of 2 with liver and GI involvement. Two
atients with skin and liver involvement did not re-
pond to therapy.
Five (25%) of 20 patients had GVHD that did not
espond to treatment. GVHD progressed in 3 patients
nos. 11, 14, and 18) and required additional therapy.
fourth patient (no. 19) received 15 doses of etaner-
ept before GVHD progressed. This patient died of
erebral hemorrhage 2 weeks after the discontinuation
f therapy and was found to have disseminated zygo-
ycosis at autopsy. A ﬁfth patient (no. 4) had stable
isease and received all 16 doses of etanercept;
VHD progressed, however, within 2 weeks of stop-
ing etanercept. Only 1 (no. 18) of the 5 patients with
rogressive GVHD survived and is now being treated
or extensive chronic GVHD. w
B&MTytokine Analysis
Cytokine analysis was performed on all 20 patients
n this study. The sTNFR1 levels were followed up
or the ﬁrst 4 weeks of therapy with etanercept. Figure
shows the ratios of sTNFR1 levels to baseline for
he 20 patients on study (15 responders and 5 nonre-
ponders). Ratios were determined by dividing the
eekly levels of sTNFR1 in each patient by the base-
ine levels (taken as the lowest of the levels for the
atient before transplantation). As a control, the ratios
f sTNFR1 for 20 patients who did not develop
VHD are shown. These patients were case-matched
or regimen intensity, histocompatibility differences
ith the donor, donor type, and time after transplan-
ation to the patients in the study. At the time of onset
f GVHD (Figure 1), there was a signiﬁcant increase
n the ratio of sTNFR1 receptor levels when com-
ared with the historical case-matched controls with
o aGVHD (P  .01). By week 2, sTNFR1 levels in
esponding patients returned to baseline, whereas
TNFR1 levels in nonresponders continued to in-
rease through the 4-week period. Differences in sT-
FR1 levels between responders and nonresponders
ere statistically signiﬁcant 4 weeks after therapy
tarted (P  .0001).
ong-Term Follow-Up
With a median follow-up of 791 days (range, 402-
043 days), 10 patients are alive and free of relapse of
heir underlying hematologic malignancy. All 10 have
hronic GVHD (6 extensive and 4 limited). Of the 10
atients who died, 4 (nos. 4, 11, 14, and 19) died of
rogressive GVHD or complications. One of these
atients had disseminated zygomycosis at autopsy.
hree patients (nos. 10, 13, and 20), all of whom had
efractory disease at the time of transplantation, re-
apsed and died of their underlying hematologic dis-
ase. Three additional deaths occurred: 1 (no. 8) was
rom a likely cardiovascular event at home (permission
or autopsy was denied) 2 months after completing
herapy. A second patient (no. 9), who developed fun-
al disease while being treated with immunosuppres-
ion for chronic GVHD of the skin, died from dis-
eminated aspergillosis 6 months after completing
herapy with etanercept. A third patient (no. 17) died
3 days after starting etanercept treatment. He devel-
ped progressive nodular disease of presumed fungal
tiology in his lung and brain, but a deﬁnitive diag-
osis was not established.
ISCUSSION
The data presented here suggest that etanercept
ay be administered safely in patients with aGVHD
nd that it is associated with a signiﬁcant response rate
hen used in combination with methylprednisolone
683
Table 1. Patient Characteristics
Patient
No. Diagnosis Disease Status* Sex/Age (y) Chemotherapy† Donor‡ Source§ Match
GVHD Stage
(Skin-Liver-Gut)
GVHD
Grade Response Doses
Reason for Stopping
Etanercept
1 NHL PR M/44 Full FD PBSC 6/6 0-2-2 III CR 16
2 NHL PR F/52 Full UD BM 6/6 0-0-1 II CR 16
3 NHL PR F/64 Reduced FD PBSC 6/6 3-0-0 II CR 7 Perforated
duodenal ulcer
4 CML CP2 M/59 Full UD BM 6/6 0-2-1 III NR 16
5 NHL Ref F/57 Full FD PBSC 6/6 3-0-0 II CR 16
6 NHL Ref M/55 Full FD PBSC 6/6 3-0-0 II CR 16
7 AML Early relapse M/44 Full FD PBSC 6/6 0-0-1 II CR 16
8 MM CR F/43 Reduced FD PBSC 6/6 1-0-1 II CR 16
9 NHL CR M/39 Full FD PBSC 6/6 0-0-1 II CR 16
10 CLL Ref M/46 Full FD PBSC 6/6 3-0-0 II CR 16
11 NHL Relapsed after
autologous
BMT
F/53 Reduced FD PBSC 6/6 0-0-2 III PD 5 Progression GVHD
12 NHL PR M/50 Full FD PBSC 6/6 3-0-0 II CR 16
13 AML Relapsed after
FD BMT
M/23 Reduced FD PBSC 6/6 3-0-1 II CR 10 Relapsed leukemia
14 MDS/AML Untreated M/55 Full FD PBSC 6/6 3-2-0 III PD 5 Progression GVHD
15 AML Early relapse F/38 Full UD PBSC 5/6 3-0-0 II CR 16
16 CLL PR M/48 Full FD PBSC 6/6 0-0-1 II CR 16
17 NHL Ref M/52 Full FD PBSC 6/6 3-0-2 III CR 11 Presumed infection
18 MDS Untreated F/15 Full UD PBSC 6/6 1-1-0 II PD 6 Progression GVHD
19 AML CR1 M/57 Full UD BM 6/6 2-0-2 III PD 15 Progression GVHD
20 AML Late relapse M/8 Full UD BM 6/6 3-0-0 II CR 12 Relapsed leukemia
NHL indicates non-Hodgkin lymphoma; CML, chronic myelogenous leukemia; AML, acute myelogenous leukemia; MM, multiple myeloma; CLL, chronic lymphocytic leukemia; MDS, myelodys-
plastic syndrome.
*Disease status as measured by the response to last chemotherapy before transplantation. PR indicates partial response; CP2, second chronic phase CML after induction chemotherapy for transformed
leukemia; Ref, refractory; early relapse, 20% blasts in marrow; late relapse, 30% blasts in marrow; CR, complete response.
†Chemotherapy used in preparative regimen: full indicates full intensity for lymphoma, cyclophosphamide, VP-16, and carmustine; for leukemia, busulfan and cyclophosphamide with or without cytosine
arabinoside. Reduced intensity included busulfan, ﬂudarabine, and total lymphoid irradiation 200 cGy.
‡FD indicates family donor; UD, unrelated donor.
§PBSC indicates peripheral blood stem cells; BM, bone marrow.
Best response to etancercept at 4 weeks; NR, no response; PD, progressive disease.
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Etanercept and Methylprednisolone for aGVHD
Bnd tacrolimus as up-front therapy for aGVHD. Of
he 20 patients treated in this setting, 15 (75%) had a
R. CRs were seen in both the FD (12/14) and UD
3/6) setting and in all 3 GVHD target organs. Pa-
ients with isolated skin or GI involvement (11/12 CR)
r both skin and GI involvement (3/4 CR) responded
ell to the combination of etanercept and methyl-
rednisolone. Responses were also noted in 1 of 2
atients with liver and GI involvement. The 5 patients
ho did not achieve a CR had GI (n  1), skin and
iver (n  2), liver and GI (n  1), and skin and GI
n 1) involvement. Because this was a pilot study, we
annot conclude that the response rates observed are
ecessarily signiﬁcantly better that what might be ob-
ained with steroids alone. Furthermore, because
rade IV GVHD was speciﬁcally excluded to better
valuate the potential toxicity associated with etaner-
ept, the rate of response may be higher than would be
nticipated if all grades of GVHD were included.
lthough a multivariate analysis in the study by Mac-
illan et al. [8] indicated that the initial grade of
VHD (II versus III/IV) was not a statistically signif-
cant factor in achieving a CR, we are reluctant to
eneralize patterns of response on the basis of this
tudy. However, the correlation between sTNFR1
atios over time and clinical outcome supports further
tudy of cytokine inhibition as a treatment for
GVHD, especially as an up-front therapy for
GVHD.
Cytokine modulation is a new strategy in the
reatment of GVHD. We have previously shown in
urine models that the inﬂammatory cytokine
NF- plays a major role in the pathophysiology of
VHD. Excessive production of TNF- may con-
ribute to tissue damage by activating immune effector
ells and by direct cytotoxicity [12,14]. These murine
odels have revealed a consistent correlation between
ncreases of TNF- and the severity of GVHD. Neu-
able 2. Response to Therapy
Variable Date
R rate 15/20 (75%)
Related 12/14 (79%)
UD 3/6 (50%)
R, aGVHD grade II
Related 10/11
UD 3/3
R, aGVHD grade III
Related 2/3
UD 0/3
R by organ involvement
Skin 7/7
GI 4/5
Skin  GI 3/4
Liver  GI 1/2
Skin  liver 0/2ralizing TNF- early in the time course of GVHD b
B&MTecreases the histologic changes in GVHD target or-
ans and improves survival [16,17].
Several clinical trials have also shown associations
etween TNF- and the development of aGVHD
fter allogeneic BMT. In a series of studies on 111
llogeneic BMT recipients, high levels of TNF- re-
eased during the conditioning regimen were predic-
ive of the severity of aGVHD. These high producers
f TNF- had a 90% incidence of grade II to IV
GVHD and a 70% mortality due to transplant-re-
ated complications [20]. As reported in other clinical
onditions, the systemic release of TNF- was mir-
ored by a release of sTNFR1, and sTNFR1 levels
orrelated with the intensity of the aGVHD. In one
tudy, patients undergoing allogeneic BMT without
VHD had sTNFR1 levels of 4.1  1.2 ng/mL,
hereas levels were increased to 8.5  2.4 ng/mL and
4.3  5.7 ng/mL in patients with grade II and grades
II to IV GVHD, respectively [20]. Our study also
hows an association between sTNFR1 levels and the
evelopment of aGVHD. The sTNFR1 levels were
ore reliable to follow once etanercept therapy was
nitiated, because the enzyme-linked immunosorbent
ssay for TNF- cross-reacts with etanercept. At the
nset of GVHD, levels of sTNFR1 were increased
ompared with baseline and continued to increase in
atients with progressive GVHD. In contrast, levels of
TNFR1 returned to baseline after 2 weeks in patients
ho responded to the administration of etanercept.
lthough these data are preliminary and need to be
onﬁrmed in a larger study, they are consistent with
ur previous work and suggest that sTNFR1 levels
ay be an effective immunologic marker for monitor-
ng the treatment of aGVHD [34]. If increasing sT-
FR1 levels correlate with a lack of response despite
igure 1. Ratios (mean  SEM) of sTNFR1 levels during the ﬁrst
weeks of therapy with etanercept. The y-axis shows the ratio of
TNFR1 levels to baseline. Ratios were determined by dividing the
eekly levels of sTNFR1 in each patient by the baseline levels
taken as the lowest pretransplantation level). Data shown are for 20
atients on study (15 responders [●] and 5 nonresponders []) and
group of historical control patients without aGVHD (Œ). *Differ-
nce between controls and GVHD subjects (P  .010); **difference
etween responders and nonresponders (P  .0001).
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6tanercept administration, then the addition of other
mmunomodulating agents may be warranted. How-
ver, the optimal duration of etanercept treatment in
esponding patients still needs to be determined.
More recently, several trials have evaluated inﬂix-
mab (Remicaid; Centocor Corp., Malvern, PA) for
he treatment of aGVHD [25-28]. Inﬂiximab is a
ouse/human chimeric antibody speciﬁc for TNF-
23] and, similarly to etanercept, has been used suc-
essfully in a broad range of inﬂammatory and auto-
mmune diseases. In the largest series to date, Couriel
t al. [28] gave inﬂiximab to 21 patients with steroid-
efractory aGVHD. The administration of inﬂiximab,
iven weekly for at least 4 doses, resulted in an im-
ressively high CR rate of 62%. Unfortunately, high
ates of fungal (48%), bacterial (81%), and viral (67%)
nfections were also observed in this heavily pretreated
roup. Others have shown similar associations be-
ween the use of inﬂiximab and infections in patients
ith GVHD. Marty et al. [35] reported that 5 (42%)
f 11 patients who received inﬂiximab for severe
VHD developed noncandidal fungal infections,
ompared with only 12% of a similar group of patients
ho did not receive inﬂiximab. In our study, 1 con-
rmed fungal infection (zygomycosis diagnosed at au-
opsy) was associated with etanercept administration.
n additional patient, who was receiving multiple im-
unosuppressive agents for chronic GVHD, died
rom aspergillosis 6 months after completing treat-
ent with etanercept. It is unclear what role the et-
nercept treatment had in the development of as-
ergillosis. One difference in the infectious disease
roﬁle seen in patients given alternative forms of
NF- blockade may be due to the different mecha-
isms of action between inﬂiximab and etanercept.
lthough both inﬂiximab and etanercept bind free
NF- molecules, only inﬂiximab binds complement
nd may also lyse target cells [36,37]. This enhanced
ytolytic activity of inﬂiximab may explain the differ-
nt infectious disease complication rate between the 2
olecules. Differences in patient populations may also
xplain differences in infection rates between our
tudy and the cited studies. In each of the reports
ssociated with high rates of infections, inﬂiximab was
dministered to heavily immunosuppressed patients
ith steroid-refractory GVHD. These patients were
robably more prone to opportunistic infections than
ur patients, thus making any comparison between
roups challenging. In either case, additional studies
ith both agents will be needed to further delineate
he infectious complications associated with their use.
Allogeneic BMT remains the only viable option
or many patients with malignant and nonmalignant
isorders, but aGVHD continues to limit the utility of
his therapy. Hence, more effective therapy is needed
or this life-threatening disorder. The use of TNF-
eutralization strategies, along with new information
86n the importance of immunomodulatory cytokines
uch as interleukin 10 [38] in the pathogenesis of
VHD, should foster novel approaches to treat this
requent and potentially fatal complication of alloge-
eic BMT.
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